Glial Cell Line-Derived Neurotrophic Factor
"Glial Cell Line-Derived Neurotrophic Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The founding member of the glial cell line-derived neurotrophic factor family. It was originally characterized as a NERVE GROWTH FACTOR promoting the survival of MIDBRAIN dopaminergic NEURONS, and it has been studied as a potential treatment for PARKINSON DISEASE.
| Descriptor ID |
D051100
|
| MeSH Number(s) |
D12.644.276.860.381.500 D12.776.467.860.381.500 D12.776.631.600.381.500 D23.529.850.381.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glial Cell Line-Derived Neurotrophic Factor".
Below are MeSH descriptors whose meaning is more specific than "Glial Cell Line-Derived Neurotrophic Factor".
This graph shows the total number of publications written about "Glial Cell Line-Derived Neurotrophic Factor" by people in this website by year, and whether "Glial Cell Line-Derived Neurotrophic Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 4 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glial Cell Line-Derived Neurotrophic Factor" by people in Profiles.
-
GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
-
Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARa-Dependent Astrocytic GDNF Pathway. J Neurosci. 2021 03 10; 41(10):2287-2300.
-
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
-
Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson's Disease Via Astrocytic GDNF. J Neuroimmune Pharmacol. 2019 09; 14(3):503-518.
-
Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
-
AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
-
Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase. J Biol Chem. 2013 Jul 19; 288(29):20843-20855.
-
Gene therapy for Huntington's disease. Neurobiol Dis. 2012 Nov; 48(2):243-54.
-
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
-
Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.